ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

OBJECTIVE: To investigate the relationship between Excision repair cross-complementation 1 (ERCC1) expression, clinicopathological features, and breast cancer prognosis in patients treated with trastuzumab. Further, we aim to explore the immune status of ERCC1 in breast cancer. METHODS: The data wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yilun, Liao, Xiaomei, Ma, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631216/
https://www.ncbi.nlm.nih.gov/pubmed/36338712
http://dx.doi.org/10.3389/fonc.2022.955719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631216/
https://www.ncbi.nlm.nih.gov/pubmed/36338712
http://dx.doi.org/10.3389/fonc.2022.955719

Ejemplares similares